Thermalytix® · The Technology
The test that sees what no one else can
AI-powered thermal imaging. No radiation. No contact. No pain. A complete breast health picture in 15 minutes.
The sensor reads your body’s heat story
A high-resolution thermal sensor is placed 3 feet in front of you — behind a privacy screen. No one enters the space. No one touches you. No one sees you.
The device captures 5 precise thermal views of the chest region in under 2 minutes. You remain fully clothed behind the screen throughout.
Zero radiation
5 thermal views
Under 2 minutes
Sensor
32°C
temperature data points per image
400,000 temperature points. Mapped precisely.
The thermal images are converted into precise temperature maps — not the visual image, but the underlying data. Every pixel becomes a data point with an exact temperature value.
This gives Thermalytix 50x greater thermal sensitivity than conventional thermography — detecting differences as small as 0.02°C. The human eye misses this entirely. The AI does not.
50x sharper than thermography
5 views mapped
Nine AI models. Running in parallel.
The temperature maps feed into Thermalytix’s proprietary AI engine — nine machine learning models running simultaneously, each trained on mammography, ultrasound, and biopsy data.
Baseline model
Patented methodology
Deep learning
9 ML models
Output score
Thermalytix is not thermography. Here is the difference.
Conventional thermography has existed for decades. Clinicians familiar with it are right to be sceptical — it has a well-documented record of high false positives, subjective interpretation, and unreliable results. Thermalytix is a different technology built on a different scientific foundation.
| Attribute | Thermalytix® | Conventional Thermography |
|---|---|---|
| Analysis method | AI-automated analysis of temperature maps — fully objectiveAI | Manual visual reading by a trained thermographer — subjective |
| Thermal sensitivity | 0.02°C — detects differences invisible to any human observer | ~1°C standard threshold |
| Sensitivity advantage | 50x greater thermal sensitivity50x | Baseline |
| Training data | Mammography, ultrasound, and biopsy data | Thermography norms only |
| Sessions required | Single session — report from one visit | Two sessions 3 months apart for baseline comparison |
| Vascular analysis | 17 unique patented vascular biomarkersPatented | Not performed |
| Reproducibility | Fully automated — quantitative, reproducible every time | High variability — dependent on thermographer skill |
| Positive Predictive Value | 70% higher than thermography in head-to-head trial+70% | Baseline |
| Clinical validation | 55+ peer-reviewed publications including The Lancet Oncology | Limited validation at comparable scale |
Head-to-head comparison: Kyoto International Conference, 2018. 303 patients. Blinded retrospective analysis.
AI Analysis Complete
The AI marks what needs attention
The annotated thermal output shows exactly what the AI found — and where. Every abnormality is spatially located, labelled, and scored. A trained radiologist reviews and certifies every output before it leaves the system.
The report arrives in 24 hours
The complete Thermalytix® report — annotated thermal images, B-Score, and the radiologist’s clinical notes — is delivered within 24 hours of screening.
It goes to the patient and, where applicable, to the referring physician. Clear. Actionable. No waiting, no uncertainty.
Women who score B4 or B5 are immediately contacted and guided toward appropriate follow-up imaging. The team follows up personally.
Report within 24 hours
Certified
Cleared, certified, and validated across 22 countries
Every clearance was obtained through independent clinical evaluation — not self-certification.
Also deployed in: Kenya · UAE · Philippines · Zambia · Sweden · Bulgaria · UK
55+ clinical studies. Published in the world’s leading journals.
Thermalytix® is not a research prototype. It is a commercially deployed, peer-reviewed medical technology. The evidence base spans multicentric trials, real-world evaluations, and community-level implementation studies across diverse patient populations.
2021 · Multicentric study
Evaluated Thermalytix against standard screening modalities in women with suspected breast cancer. Published BMJ Open 2021;11(10):e052098.
2020 · Observational study
Clinical efficacy for detecting breast cancer in symptomatic and asymptomatic women. JCO Global Oncology, Oct 2020;6:1472-1480.
2023 · Prospective evaluation
Breast thermography enhanced by novel ML technique for screening breast abnormalities at secondary care hospital level.
2022 · Real-world evaluation
AI-based breast cancer screening in a community setting. Lancet Oncology, 2022 Jul 1;23:S20.
2025 · Punjab programme
Real-world evaluation across 15,000+ women over 18 months. Thermalytix identified 3x more cancers than standard Clinical Breast Examination.
2022 · Conference presentation
Automated risk stratification system for breast cancer screening using Thermalytix. San Antonio Breast Cancer Symposium, December 2022.
- Sensitivity and specificity non-inferior to current standard screening methods
- 25% better sensitivity than 2D mammography in women with dense breasts
- Detects tumours as small as 4mm — vs 25mm minimum by physical examination
- 3x more cancers identified than Clinical Breast Examination in Punjab study (2025)
- 70% increase in Positive Predictive Value over thermography (Kyoto, 2018)
- 100% patient satisfaction in real-world evaluation studies
Who we work with
Thermalytix® is deployed across hospitals, corporates, communities, and homes.